-DOCSTART- -X- O
The -X- _ O
lack -X- _ O
of -X- _ O
an -X- _ O
animal -X- _ O
model -X- _ O
for -X- _ O
human -X- _ B-Patient
norovirus -X- _ I-Patient
( -X- _ I-Patient
HuNoV -X- _ I-Patient
) -X- _ I-Patient
has -X- _ O
hindered -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
therapeutic -X- _ O
strategies. -X- _ O
This -X- _ O
study -X- _ O
demonstrated -X- _ O
that -X- _ O
a -X- _ O
commonly -X- _ O
used -X- _ O
cholesterol-lowering -X- _ O
statin -X- _ O
medication -X- _ O
, -X- _ O
simvastatin -X- _ B-Intervention
, -X- _ O
which -X- _ O
increases -X- _ O
HuNoV -X- _ O
replication -X- _ O
in -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
replicon -X- _ O
system -X- _ O
, -X- _ O
also -X- _ O
enhances -X- _ B-Outcome
HuNoV -X- _ B-Patient
infectivity -X- _ I-Patient
in -X- _ I-Patient
the -X- _ I-Patient
gnotobiotic -X- _ I-Patient
( -X- _ I-Patient
Gn -X- _ I-Patient
) -X- _ I-Patient
pig -X- _ I-Patient
model. -X- _ I-Patient
In -X- _ O
contrast -X- _ O
, -X- _ O
oral -X- _ O
treatment -X- _ O
with -X- _ O
interferon -X- _ B-Intervention
( -X- _ I-Intervention
IFN -X- _ I-Intervention
) -X- _ I-Intervention
-α -X- _ I-Intervention
reduces -X- _ O
HuNoV -X- _ B-Patient
infectivity. -X- _ I-Patient
Young -X- _ B-Patient
piglets -X- _ I-Patient
, -X- _ O
all -X- _ O
with -X- _ O
A -X- _ O
or -X- _ O
H1 -X- _ O
histo-blood -X- _ O
group -X- _ O
antigens -X- _ O
on -X- _ O
enterocytes -X- _ O
, -X- _ O
were -X- _ O
treated -X- _ O
orally -X- _ O
with -X- _ O
8 -X- _ B-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
/ -X- _ I-Intervention
day -X- _ I-Intervention
of -X- _ I-Intervention
simvastatin -X- _ I-Intervention
; -X- _ O
5 -X- _ O
days -X- _ O
later -X- _ O
, -X- _ O
the -X- _ O
pigs -X- _ O
were -X- _ O
inoculated -X- _ O
orally -X- _ O
with -X- _ O
a -X- _ O
GII.4 -X- _ B-Patient
HuNoV -X- _ I-Patient
( -X- _ I-Patient
HS194 -X- _ I-Patient
/ -X- _ I-Patient
2009 -X- _ I-Patient
/ -X- _ I-Patient
US -X- _ I-Patient
strain -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
then -X- _ O
treated -X- _ B-Intervention
with -X- _ I-Intervention
simvastatin -X- _ I-Intervention
for -X- _ I-Intervention
5 -X- _ I-Intervention
more -X- _ I-Intervention
days. -X- _ I-Intervention
Simvastatin -X- _ B-Outcome
induced -X- _ I-Outcome
significantly -X- _ I-Outcome
earlier -X- _ I-Outcome
onset -X- _ I-Outcome
and -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
HuNoV -X- _ I-Outcome
fecal -X- _ I-Outcome
shedding -X- _ I-Outcome
in -X- _ I-Outcome
treated -X- _ I-Outcome
pigs -X- _ I-Outcome
, -X- _ I-Outcome
frequently -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
fecal -X- _ I-Outcome
viral -X- _ I-Outcome
titers. -X- _ I-Outcome
Simvastatin -X- _ I-Outcome
impaired -X- _ I-Outcome
poly -X- _ I-Outcome
( -X- _ I-Outcome
I -X- _ I-Outcome
: -X- _ I-Outcome
C -X- _ I-Outcome
) -X- _ I-Outcome
-induced -X- _ I-Outcome
IFN-α -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
macrophages -X- _ I-Outcome
or -X- _ I-Outcome
dendritic -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
possibly -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
lowered -X- _ I-Outcome
toll-like -X- _ I-Outcome
receptor -X- _ I-Outcome
( -X- _ I-Outcome
TLR -X- _ I-Outcome
) -X- _ I-Outcome
3 -X- _ I-Outcome
expression -X- _ I-Outcome
; -X- _ I-Outcome
however -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
mechanisms -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
interferon -X- _ I-Outcome
regulatory -X- _ I-Outcome
factor -X- _ I-Outcome
3 -X- _ I-Outcome
or -X- _ I-Outcome
nuclear -X- _ I-Outcome
factor -X- _ I-Outcome
kappa -X- _ I-Outcome
B -X- _ I-Outcome
signaling -X- _ I-Outcome
pathway. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
the -X- _ O
enhanced -X- _ O
, -X- _ O
earlier -X- _ B-Outcome
infectivity -X- _ I-Outcome
of -X- _ I-Outcome
HuNoV -X- _ I-Outcome
in -X- _ I-Outcome
simvastatin-treated -X- _ I-Outcome
pigs -X- _ I-Outcome
coincided -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
inhibitory -X- _ I-Outcome
effect -X- _ I-Outcome
of -X- _ I-Outcome
simvastatin -X- _ I-Outcome
on -X- _ I-Outcome
innate -X- _ I-Outcome
immunity. -X- _ I-Outcome
In -X- _ O
contrast -X- _ O
to -X- _ O
the -X- _ O
increased -X- _ O
HuNoV -X- _ O
shedding -X- _ O
that -X- _ O
simvastatin -X- _ O
induced -X- _ O
, -X- _ O
viral -X- _ B-Outcome
shedding -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
period -X- _ I-Outcome
was -X- _ I-Outcome
reduced -X- _ I-Outcome
or -X- _ I-Outcome
curtailed -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
HuNoV-inoculated -X- _ I-Outcome
pigs -X- _ I-Outcome
pre- -X- _ I-Outcome
treated -X- _ I-Outcome
/ -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
human -X- _ I-Outcome
IFN-α. -X- _ I-Outcome
Our -X- _ I-Outcome
findings -X- _ I-Outcome
are -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
to -X- _ I-Outcome
indicate -X- _ I-Outcome
that -X- _ I-Outcome
IFN-α -X- _ I-Outcome
has -X- _ O
potential -X- _ O
as -X- _ O
antiviral -X- _ B-Outcome
therapy -X- _ I-Outcome
against -X- _ I-Outcome
HuNoV. -X- _ I-Outcome
Based -X- _ O
on -X- _ O
these -X- _ O
intriguing -X- _ O
and -X- _ O
novel -X- _ O
findings -X- _ O
using -X- _ O
the -X- _ O
Gn -X- _ B-Patient
pig -X- _ I-Patient
model -X- _ I-Patient
, -X- _ O
we -X- _ O
confirmed -X- _ O
that -X- _ O
HuNoV -X- _ B-Outcome
infectivity -X- _ I-Outcome
is -X- _ I-Outcome
altered -X- _ I-Outcome
by -X- _ I-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
simvastatin -X- _ I-Outcome
or -X- _ I-Outcome
IFN-α. -X- _ I-Outcome
Collectively -X- _ O
, -X- _ O
these -X- _ O
findings -X- _ O
indicate -X- _ O
that -X- _ O
Gn -X- _ O
pigs -X- _ O
are -X- _ O
a -X- _ O
useful -X- _ O
model -X- _ O
to -X- _ O
test -X- _ O
immunomodulators -X- _ O
or -X- _ O
efficacy -X- _ O
of -X- _ O
antivirals -X- _ O
against -X- _ O
HuNoV -X- _ O
. -X- _ O

